<SEC-DOCUMENT>0001104659-19-061698.txt : 20191108
<SEC-HEADER>0001104659-19-061698.hdr.sgml : 20191108
<ACCEPTANCE-DATETIME>20191108161636
ACCESSION NUMBER:		0001104659-19-061698
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20191107
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191108
DATE AS OF CHANGE:		20191108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		191204259

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm1921482d2_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
November 7, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B>Applied
DNA Sciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD STYLE="width: 33%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(State or Other Jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of Incorporation)</P></TD>
    <TD STYLE="width: 34%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>001-36745</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="width: 33%; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>59-2262718</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Identification No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">50 Health Sciences Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Stony Brook, New York 11790</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of Principal Executive Offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">631-240-8800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Not Applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #231F20">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #FEFEFE">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>Trading <BR>
Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.001 par value</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APDN</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NASDAQ Capital Market</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase Common Stock</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APDNW</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NASDAQ Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company</FONT>&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</FONT>&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item 5.02.</B></FONT></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify; padding-top: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Applied
DNA Sciences, Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) </FONT>has commenced a comprehensive review of the Company&rsquo;s
corporate governance, business, operations and capital allocation in consultation with certain holders of its common stock and
secured notes. <FONT STYLE="background-color: white">As a first step, on November 7, 2019, Charles S. Ryan resigned from his position
as a director of the Board of Directors (the &ldquo;<B><I>Board</I></B>&rdquo;) of the Company and Scott L. Anchin was appointed
as a director on the same date, both effective immediately. The resignation of Mr. Ryan did not involve any disagreement with the
Company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Mr.
Anchin will be serving on the Board as a non-employee director. </FONT>As has been the policy with other non-employee directors,
Mr. Anchin will be granted annually a ten year stock option, that will fully vest after one year, to purchase a number of shares
of common stock having a fair value of $75,000 as determined using the Black Scholes valuation method or as otherwise determined
by the compensation committee of the Board. <FONT STYLE="background-color: white">In connection with Mr. Anchin&rsquo;s appointment
to the Board, he will also enter into the Company&rsquo;s standard form of indemnification agreement.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company also expects to enter into a
consulting agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) with a term of up to one year with Mr. Anchin. The Agreement is
expected to provide that Mr. Anchin will receive cash and/or stock options as compensation in exchange for providing certain advisory
and consulting services to the Company with respect to the Company&rsquo;s business strategy as well as the Company&rsquo;s capital
allocation, operating budget, and cash management. The final compensation terms have yet to be determined and the Board intends
to evaluate the independence of Mr. Anchin once the terms of the Agreement are finalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no understanding
or arrangement between Mr. Anchin and any other person or persons with respect to his appointment as a director and there are no
family relationships between Mr. Anchin and any other director or executive officer. Except as described above, there are no related
party transactions between Mr. Anchin and the Company that would require disclosure under Item 404(a) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
appointment of Mr. Anchin as a director of the Board, the Board also intends over the next four months to replace two more of its
existing directors while maintaining an eight person Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item 7.01.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On November 8, 2019,
the Company issued a press release announcing Mr. Ryan&rsquo;s resignation and Mr. Anchin&rsquo;s appointment. The press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The information related
to the press release furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed &ldquo;filed&rdquo; for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), or otherwise
subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item 9.01.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(<I>d)</I></TD><TD STYLE="text-align: justify"><I>Exhibits</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="tm1921482d2_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></A></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><A HREF="tm1921482d2_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">Press Release of Applied DNA Sciences, Inc. dated November 8, 2019. </FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Applied DNA Sciences, Inc. </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Registrant) </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; width: 50%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 30%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 15%; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ James A. Hayward </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">James A. Hayward<BR>
Chief Executive Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: November 8, 2019</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm1921482d2_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1 </B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #333333"><FONT STYLE="color: Black">Applied
DNA Sciences Announces Appointment of Scott L. Anchin to Board of Directors</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: rgb(51,51,51)">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0070C0; text-align: center"><FONT STYLE="font-weight: normal; color: Black">Appointment
follows resignation of Director Dr. Charles Ryan </FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0070C0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>STONY BROOK,
N.Y., November 8, 2019</B>&nbsp;&ndash;&nbsp; <U>Applied DNA Sciences, Inc.</U>&nbsp;(NASDAQ: APDN) (&ldquo;Applied DNA&rdquo;
or the &ldquo;Company&rdquo;) <FONT STYLE="background-color: white">a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing
for product authenticity, traceability solutions and nucleic acid-based biotherapeutic research</FONT>, today announced the appointment
of Scott L. Anchin to its Board of Directors following the resignation of Director Dr. Charles Ryan. The Company expects Mr. Anchin
will also be engaged as a strategic advisor to the Company. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A"><FONT STYLE="color: Black; background-color: white">Mr.
Anchin is a restructuring professional with more than twenty years of leadership experience spanning a variety of industries.
Mr. Anchin is currently a partner at Cormont Strategic Services, LLC and formally worked for Alvarez &amp; Marsal North America,
LLC, a global professional services firm specializing in turnaround and interim management and performance improvement. Mr. Anchin
started his career in public accounting with Anchin, Block &amp; Anchin LLP, where he audited financial statements for manufacturing,
real estate, retail and consumer products companies. Mr. Anchin has advised on many notable restructuring engagements including
Lehman Brothers Holdings Inc., Fieldwood Energy, Vanguard Natural Resources, Chaparral Energy, Cengage Learning and O.W. Bunker,
among others. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A"><FONT STYLE="color: Black; background-color: white">Mr.
Anchin has a Bachelor of Science in Accounting from the Wharton School of Business at the University of Pennsylvania and an MBA
with a concentration in Management from Columbia Business School. He is also a non-active Certified Public Accountant (CPA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A"><FONT STYLE="color: Black; background-color: white">&ldquo;Dr.
Ryan has been a trusted colleague and advisor for many years, and we thank him for his thoughtful service on our Board,&rdquo;
said Dr. James A. Hayward, President, Chairman and Chief Executive Officer of Applied DNA. &ldquo;It has been an honor and a privilege
to be associated with Dr. Ryan and we wish him all the best in his next endeavor.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A"><FONT STYLE="color: Black; background-color: white">&ldquo;When
one door closes, another opens, and we are thrilled to have Mr. Anchin join our Board and look forward to him starting work as
a strategic advisor. Mr. Anchin has a demonstrated track record of driving performance improvements and increasing shareholder
value,&rdquo; said Dr. Hayward. &ldquo;We are pleased to welcome Mr. Anchin at this important next stage of Applied DNA&rsquo;s
evolution.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #0A0A0A"><FONT STYLE="color: Black; background-color: white">&ldquo;Having
spent many years advising emerging companies, I am extremely pleased to join Applied DNA, which I believe has the potential to
transform the track-and-trace and nucleic acid-based biotherapeutics markets,&rdquo; said Scott Anchin. &ldquo;I look forward
to working with the Applied DNA team to build a world-class company.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>About Applied
DNA Sciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Applied DNA
is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product
genotyping, and pre-clinical nucleic acid-based therapeutic drug candidate<FONT STYLE="background-color: white">s.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #222222"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: Black">Applied
DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect
products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting,
fraud and diversion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">Visit <U>adnas.com
</U>for more information. Follow us on <U>Twitter</U> and <U>LinkedIn</U>. Join our <U>mailing list</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: Black">Common
stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Black">The statements
made by Applied DNA in this press release may be &ldquo;forward-looking&rdquo; in nature within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA&rsquo;s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control
of Applied DNA. Actual results could differ materially from those projected due to the substantial doubt relating to Applied DNA&rsquo;s
ability to continue as a going concern, our ability to successfully enter into commercial contracts for the implementation of
our CertainT&reg; platform, the possibility of failure to make timely payment on its outstanding secured convertible notes and
resulting enforcement by noteholders of remedies on collateral which includes substantially all of Applied DNA&rsquo;s assets,
the Company&rsquo;s history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent
in research and development, future clinical data and analysis, including whether any of Applied DNA&rsquo;s product candidates
will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and
Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they
will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, uncertainties relating to its ability
to maintain its NASDAQ listing in light of delisting notices received and its recent hearing, and various other factors detailed
from time to time in Applied DNA&rsquo;s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18,
2018, as amended, and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019, May 9, 2019 and August 13, 2019,
and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly
any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence
of unanticipated events, unless otherwise required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black"><B>investor contact:&nbsp;</B>Sanjay
M. Hurry, LHA Investor Relations<B>,&nbsp;</B>212-838-3777,&nbsp;<U>shurry@lhai.com</U><BR><B>web:&nbsp;</B>www.adnas.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A"><FONT STYLE="color: Black"><B>twitter:&nbsp;</B>@APDN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A"><FONT STYLE="color: Black; background-color: #F8F8F8">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A"><FONT STYLE="color: Black; background-color: #F8F8F8"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #0A0A0A"><FONT STYLE="color: Black; background-color: #F8F8F8">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ] U(# 2(  A$! Q$!_\0
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MQ"WCQ]>U/0I=5T?P;8>()-1\))H7P^LO$%\NC#1-5OC;:8;U8#^[= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!C:]XBT#PMI\FK^)=;TCP]I,+*D^J:YJ=CI&G0,X8HLU[J-Q;6T;.
M5*HK2[F/08#$97A3Q]X+\>:3:>(/ OBKP]XV\/7TCQ6?B'P?K6F>)M N)4 9
MXXM9T6[O=.=U0JS*+G*^9"C8EN+>.7XO_P""A]_\/M+^'OP'U'XJQ:#+\/=/
M_:Z_9[U#Q6?%.EPZQX;M=.LO%,TL.IZ[8W%K>6RZ9I>J?V=?3:C>0&RT>6&#
M5;R:VM[-[B+DOV:[OX<>+?VO?CO\1?V:9?#=Y\ -6^$?PMT'Q[XM^'<-E'\(
MOB!^T5IWC#QO?'5/"6HZ%;6_A;QCXVT#X5WOAO1OB3XX\/\ ]I0W%A>_#/PG
MJ&NWVH>$)M*T( _1?5=:TO18H9=3O;6R6YDFAM1<W$%L;J:WLKK4KB"W:XDB
MCEFATVQO]0DB5_,6QL;RZ*^3:SNE7PUXI\,^,]"L/%'@_P 0Z'XJ\-:K%)-I
M?B'PWJ^G:[H>I0PSRVTLVGZOI5S=Z?>117,$]O));W,B)/#+$Y$D;J/CK]M/
MP3HGQ#US]C'PKXGTB?7/#-[^U]I-SX@TP17,NFWNG:;^SQ^T7J"V/B-80UM-
MX9U2^M[+2=;T[5@VC:]::@WAS48YH-8,$OU]X6\->&_".@V^A>$_#N@^%=$M
MGO;B'1?"^EZ;HFCVUUJ-U/J.IS6MCI=O:6,<M[J-U=7UW<)!&UW>7$]W.6FF
MD=@#)USXH?#CPSK>@^&?$GCKPCX>\3>*9!#X7\,ZYXCT?2O$GB65IUM4A\.Z
M!?7L&KZY/)=.EI';:79W=P]VZV:Q&ZS".X1Q(NY<C!*D'J"IP1P2#SW!(/4$
MC!K^?WXV>#_AO/\ &7]N3P=^U!^TEX6^!TWQA\4Z9<>#].^(?P8^''BK7OB-
M\$+SX2^!O#7@M/@/XU\6:5>>*_$^I^#O&\'CFUL/ '@"XU7Q/X(^*$LWB33_
M  W87OC.QO?$'[J?#VV>S\"^#[.36/$?B&2S\,:!:2^(/&%K+8>+-=DM=(L[
M=M:\3V$]GI\UCXBU4Q_;]<LYM/T^>VU6XO(9["RG22VB ([/XD_#[4/&%_\
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M)/[$WC'Q-^TK)X?^'WA""#QO\:O"G@;XEW'B3Q%X1\32>%]-\5>$O"^M>,?
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M=!%IJ@!_2^)XCMP^=VS;A6.=XRIX' /0L<!3@,02!2^;'G&[NR\*Q&5#%AD
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MCCXC>%O#5F9-.>_C\01Z#K*:)I(6"760MCI$=K(]Y';-_%A_P3C_ &G/V0_
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M-%=.RX?BU;_H.AYG],?_  LWX<8S_P )_P""O7GQ3H8_/-]Q^-)_PL[X;?\
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M[F#@9_U4'/3_ *9<>G?C\JRFM[;)_P!'M3SU,%OG_P!$UL_HTX3_ **[,O\
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M4\OG#Q!X6\36$XFAM=(\0K)I6OW,<VDS+?"^T7]#/V%_V;OVX?VH/^"A4O\
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M:A+N9F%LUQ&Q8_TK-&&.2>@P!C@#'Y@YP<J5.!@$#-,, 8$%B03G!52 1P,
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M_!KXRX<?\*;^+Y)8GY?A;X^Z$'&0/#W!/Y^GK5%O@S\9@6/_  IGXPCDY/\
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M?%W)X[G_ (0\#GUK_2-,([.R_3O^>:/(7KGG^]CG/KUZUM_Q.MQ)TX"R=?\
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MGF-'!_V+E6'HU\1*A/"J-:=/,)R:]E4?O-5)1C=0E%I0+]%%%?RR?U0%%%%
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<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
